Compare AbbVie Inc (ABBV) vs Global X Robo Global Robotics & Automation ETF (ROBO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Global X Robo Global Robotics & Automation ETF — how do they compare? AbbVie Inc trades at $253.68 (market cap $449.91B), while Global X Robo Global Robotics & Automation ETF trades at $80.67. The key difference: AbbVie Inc pays a 2.72% dividend while Global X Robo Global Robotics & Automation ETF pays none, and AbbVie Inc is trading nearer its 52-week high, Global X Robo Global Robotics & Automation ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | ROBO | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | Sector/Thematic |
52-Week High | $261.07 | $90.34 |
52-Week Low | $184.85 | $60.15 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
ROBO trades at $86.19, up 3.36% today, with a bullish technical signal from moving averages and neutral oscillators. Recent news highlights the ETF's rebalancing toward AI infrastructure and physical automation themes, positioning it to benefit from the expanding robotics and AI ecosystem. Key support lies at $85, with resistance at $87.
The outlook is positive, driven by thematic tailwinds in robotics and AI infrastructure, though valuation metrics are unavailable. Risks include cyclical exposure and reliance on AI adoption. Analyst sentiment is cautiously optimistic, with institutional interest growing in physical AI themes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Global X Robo Global Robotics & Automation ETF
ROBO is a thematic ETF that tracks the global robotics and automation industry. It provides diversified exposure to companies leading in industrial robotics, 3D printing, and surgical systems, with holdings like Intuitive Surgical and Zebra Technologies.
Read more on ROBO →
